Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

Income Statement

Follow revenue through to earnings.

Revenue

$377.18M

FY 2025 · Annual

+22.6% YoY

Operating Income

$20.88M

FY 2025 · Annual

Net Income

$2.86M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue225.46M205.62M245.32M307.75M377.18M
Cost of Revenue23.97M17.56M25.21M36.66M45.63M
Gross Profit201.49M188.06M220.1M271.09M331.56M
Gross Margin89.4%91.5%89.7%88.1%87.9%
Research & Development79.78M52.53M68.91M86.1M98.08M
Selling, General & Admin54.56M68.85M87.5M102.74M117.44M
Operating Expenses186.12M169.83M225.49M280.02M309.75M
Depreciation & Amortization22.23M13.19M15.93M16.64M10.76M
EBITDA55.3M33.53M9.88M16.89M31.7M
EBITDA Margin24.5%16.3%4.0%5.5%8.4%
Operating Income15.37M18.23M(5.39M)(8.93M)20.88M
Operating Margin6.8%8.9%-2.2%-2.9%5.5%
Interest Income59.99K85K3.53M5.92M2.56M
Interest Expense7M5.36M5.96M9.05M21.31M
Other Income / Expenses10.79M(3.25M)(6.63M)133.58K(8.03M)
Income Before Tax26.16M14.99M(12.01M)(8.79M)12.88M
Pre-Tax Margin11.6%7.3%-4.9%-2.9%3.4%
Income Tax Expense8.03M1.31M(1.46M)3.47M10.34M
Net Income18.13M13.67M(10.55M)(12.26M)2.86M
Net Margin8.0%6.7%-4.3%-4.0%0.8%
EPS (Basic)0.230.17(0.14)(0.18)0.04
EPS (Diluted)0.210.16(0.14)(0.18)0.04
Weighted Avg Shares87.64M82.54M65.7M68.92M71.32M
Weighted Avg Shares (Diluted)87.64M84.28M65.7M68.92M71.32M

PHAR Earnings Waterfall · TTM

NASDAQ:PHAR · Revenue to Net Income

Key Ratios

EPS$0.18
Gross Margin87.8%
Net Margin2.6%
P/E Ratio17.4
P/S Ratio11.2

Analysis

$369.4M of revenue converted into $12.3M of net income for the selected period. Gross margin is 87.8% and net margin is 2.6%, showing how much revenue survives after costs and taxes. EPS is $0.18, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 6, 2026
6-K6-K filingOct 27, 2026
6-K6-K filingOct 22, 2026
6-K6-K filingOct 14, 2026
6-K6-K filingSep 29, 2026

How much revenue does PHAR generate?

Pharming Group N.V. (PHAR) reported $377.18M of revenue in fiscal 2025.

Is PHAR profitable?

Pharming Group N.V. (PHAR) reported $2.86M of net income, with a net margin of 0.8%.